COST-EFFECTIVENESS OF PHARMACOLOGIC TREATMENT OF OVERACTIVE BLADDER

被引：0
|
作者：
Malone, D. C. [1 ]
Armstrong, E. P. [1 ]
Bui, C. [2 ]
机构：
[1] Univ Arizona, Tucson, AZ USA
[2] Astellas Pharma US Inc, Deerfield, IL USA
来源：
VALUE IN HEALTH | 2012年 / 15卷 / 04期
关键词：
D O I：
10.1016/j.jval.2012.03.838
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A155 / A155
页数：1
相关论文
共 50 条
  • [21] COST-EFFECTIVENESS OF TREATING OVERACTIVE BLADDER WITH MIRABEGRON VERSUS ANTIMUSCARINICS IN MEXICO
    Ng, D. B.
    Parise, H.
    Dea, K.
    Espinosa, R.
    Anaya, P.
    Gooch, K.
    VALUE IN HEALTH, 2018, 21 : S266 - S267
  • [22] COST-EFFECTIVENESS ANALYSES FOR REFRACTORY OVERACTIVE BLADDER: A SYSTEMATIC LITERATURE REVIEW
    Yehoshua, A.
    Malone, D. C.
    Gillard, P.
    Globe, D.
    VALUE IN HEALTH, 2013, 16 (03) : A182 - A182
  • [23] Cost-effectiveness analysis of pharmacologic treatment of fibromyalgia in Mexico
    Arreola Ornelas, Hector
    Rosado Buzzo, Alfonso
    Garcia, Lourdes
    Dorantes Aguilar, Javier
    Contreras Hernandez, Iris
    Mould Quevedo, Joaquin F.
    REUMATOLOGIA CLINICA, 2012, 8 (03): : 120 - 127
  • [24] Cost-effectiveness of overactive bladder treatments: from the US payer perspective
    Murray, Brian
    Hessami, Sam H.
    Gultyaev, Dmitry
    Lister, Johanna
    Dmochowski, Roger
    Gillard, Kristin Khalaf
    Stanisic, Sanja
    Tung, Amy
    Boer, Robert
    Kaplan, Steven
    JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2019, 8 (01) : 61 - 72
  • [25] NEUROSTIMULATION TREATMENT FOR OVERACTIVE BLADDER: AN EVALUATION OF COST EFFECTIVENESS DATA
    MacDiarmid, Scott
    Martinson, Melissa
    Black, Edward
    JOURNAL OF UROLOGY, 2012, 187 (04): : E478 - E478
  • [26] Optimizing quality of care and cost effectiveness in the treatment of overactive bladder
    不详
    AMERICAN JOURNAL OF MANAGED CARE, 2001, 7 (02): : S43 - S45
  • [27] NEUROSTIMULATION TREATMENT FOR OVERACTIVE BLADDER: AN EVALUATION OF COST EFFECTIVENESS DATA
    MacDiarmid, Scott
    Martinson, Melissa
    Black, Edward
    NEUROUROLOGY AND URODYNAMICS, 2013, 32 (02) : 112 - 112
  • [28] COST EFFECTIVENESS OF VIBEGRON FOR THE TREATMENT OF OVERACTIVE BLADDER IN THE UNITED STATES
    Chen, J., V
    Klein, T. M.
    Mudd, P.
    VALUE IN HEALTH, 2021, 24 : S235 - S235
  • [29] OnabotulinumtoxinA in the treatment of overactive bladder: a cost-effectiveness analysis versus best supportive care in England and Wales
    Nick Freemantle
    Kristin Khalaf
    Clara Loveman
    Sanja Stanisic
    Dmitry Gultyaev
    Johanna Lister
    Marcus Drake
    The European Journal of Health Economics, 2016, 17 : 911 - 921
  • [30] The overactive bladder: Pharmacologic basis of drug treatment
    Andersson, KE
    UROLOGY, 1997, 50 (6A) : 74 - 84
12345